{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "https://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpModified.=2018-07-09T15%3A11%3A03.464Z&tablingMemberConstituency=Brighton%2C+Pavilion&max-answer.dateOfAnswer=2018-11-20", "definition" : "https://eldaddp.azurewebsites.net/meta/answeredquestions.text?max-ddpModified.=2018-07-09T15%3A11%3A03.464Z&tablingMemberConstituency=Brighton%2C+Pavilion&max-answer.dateOfAnswer=2018-11-20", "extendedMetadataVersion" : "https://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpModified.=2018-07-09T15%3A11%3A03.464Z&tablingMemberConstituency=Brighton%2C+Pavilion&_metadata=all&max-answer.dateOfAnswer=2018-11-20", "first" : "https://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&max-ddpModified.=2018-07-09T15%3A11%3A03.464Z&tablingMemberConstituency=Brighton%2C+Pavilion&max-answer.dateOfAnswer=2018-11-20", "hasPart" : "https://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpModified.=2018-07-09T15%3A11%3A03.464Z&tablingMemberConstituency=Brighton%2C+Pavilion&max-answer.dateOfAnswer=2018-11-20", "isPartOf" : "https://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpModified.=2018-07-09T15%3A11%3A03.464Z&tablingMemberConstituency=Brighton%2C+Pavilion&max-answer.dateOfAnswer=2018-11-20", "items" : [{"_about" : "http://data.parliament.uk/resources/934971", "AnsweringBody" : [{"_value" : "Department for International Trade"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/934971/answer", "answerText" : {"_value" : "
The Department for International Trade, Defence and Security Organisation has identified the following core markets for 2018-19 with defence and security opportunities:<\/p>
Australia
Austria
Bahrain
Belgium
Canada
France
Germany
India
Indonesia
Italy (lead for Mediterranean Defence Network Defence includes Spain & Portugal)
Japan
Kuwait
Latin America (Columbia, Brazil, Chile, Peru, Panama, Argentina, Mexico)
Malaysia
New Zealand
Netherlands
North Africa (Algeria, Tunisia, Egypt)
Oman
Philippines
Poland (within Central European Network and including Czech Republic, Romania, Slovakia, Bulgaria)
Qatar
Saudi Arabia
Singapore
South Korea
Southern Africa (South Africa, Botswana, Mozambique, Angola)
Sweden (lead for Nordic Baltic Network including Finland, Norway, Denmark, Lithuania, Estonia, Latvia)
Switzerland
Thailand
Turkey
United Arab Emirates
United States of America<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1482", "label" : {"_value" : "Biography information for Graham Stuart"}
}
, "answeringMemberConstituency" : {"_value" : "Beverley and Holderness"}
, "answeringMemberPrinted" : {"_value" : "Graham Stuart"}
, "dateOfAnswer" : {"_value" : "2018-07-12", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-07-12T16:47:11.677Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "202"}
, "answeringDeptShortName" : {"_value" : "International Trade"}
, "answeringDeptSortName" : {"_value" : "International Trade"}
, "date" : {"_value" : "2018-07-05", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Defence and Security Organisation"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for International Trade, what the Defence and Security Organisation core markets are for 2018-19; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/3930", "label" : {"_value" : "Biography information for Caroline Lucas"}
}
, "tablingMemberConstituency" : {"_value" : "Brighton, Pavilion"}
, "tablingMemberPrinted" : [{"_value" : "Caroline Lucas"}
], "uin" : "161130"}
, {"_about" : "http://data.parliament.uk/resources/934703", "AnsweringBody" : [{"_value" : "Department for Transport"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/934703/answer", "answerText" : {"_value" : "
Govia Thameslink Railway (GTR) has declassified first class areas on peak time trains on the Thameslink and Great Northern routes of operation. As is usual industry practice, GTR will continue to declassify first class areas on Southern and Gatwick Express services in times of disruption which it did on Thursday 5 July. Also, on board staff are empowered to take such decisions on a service by service basis.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4039", "label" : {"_value" : "Biography information for Lord Johnson of Marylebone"} } , "answeringMemberConstituency" : {"_value" : "Orpington"} , "answeringMemberPrinted" : {"_value" : "Joseph Johnson"} , "dateOfAnswer" : {"_value" : "2018-07-11", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-07-11T13:07:16.937Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "27"} , "answeringDeptShortName" : {"_value" : "Transport"} , "answeringDeptSortName" : {"_value" : "Transport"} , "date" : {"_value" : "2018-07-04", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Railways: Standards"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Transport, with reference to the letter of 28 June 2018 from the Minister of State for Transport to hon. Members on the declassification of first class trains on Thameslink and Great Northern Services, whether that policy applies to (a) Southern and (b) Gatwick Express services; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3930", "label" : {"_value" : "Biography information for Caroline Lucas"} } , "tablingMemberConstituency" : {"_value" : "Brighton, Pavilion"} , "tablingMemberPrinted" : [{"_value" : "Caroline Lucas"} ], "uin" : "160728"} , {"_about" : "http://data.parliament.uk/resources/934725", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/934725/answer", "answerText" : {"_value" : "
Naloxone is a prescription-only medicine and it is on this basis that any new nasal naloxone products would be available when brought to the United Kingdom market. Under regulations that came into force in October 2015, people employed or engaged in the provision of drug treatment services can, as part of their role, supply naloxone that has been obtained by their drug service to others, as long as it is supplied for the purpose of being available to save life in an emergency. A prescription is not needed for the naloxone to be supplied in this way.<\/p>
<\/p>
There has been no formal assessment of the decision of the European Medicines Agency to approve nasal forms of naloxone, however, officials from the Department, the Medicines and Healthcare products Regulatory Agency and Public Health England (PHE) continue to work together to identify the best available legislative option to enable nasal naloxone to be provided on the same basis as injectable naloxone.<\/p>
<\/p>
Local authorities are responsible for commissioning drug treatment services and interventions to reduce drug-related harm, including naloxone, based on local need. PHE continues to provide advice and support to local authorities on expanding naloxone provision.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2018-07-11", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "160730"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-07-11T11:32:10.45Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-07-04", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Naloxone"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will bring forward legislative proposals to enable the provision of new nasal forms of naloxone to help prevent deaths from opioid overdose; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3930", "label" : {"_value" : "Biography information for Caroline Lucas"} } , "tablingMemberConstituency" : {"_value" : "Brighton, Pavilion"} , "tablingMemberPrinted" : [{"_value" : "Caroline Lucas"} ], "uin" : "160729"} , {"_about" : "http://data.parliament.uk/resources/934726", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/934726/answer", "answerText" : {"_value" : "
Naloxone is a prescription-only medicine and it is on this basis that any new nasal naloxone products would be available when brought to the United Kingdom market. Under regulations that came into force in October 2015, people employed or engaged in the provision of drug treatment services can, as part of their role, supply naloxone that has been obtained by their drug service to others, as long as it is supplied for the purpose of being available to save life in an emergency. A prescription is not needed for the naloxone to be supplied in this way.<\/p>
<\/p>
There has been no formal assessment of the decision of the European Medicines Agency to approve nasal forms of naloxone, however, officials from the Department, the Medicines and Healthcare products Regulatory Agency and Public Health England (PHE) continue to work together to identify the best available legislative option to enable nasal naloxone to be provided on the same basis as injectable naloxone.<\/p>
<\/p>
Local authorities are responsible for commissioning drug treatment services and interventions to reduce drug-related harm, including naloxone, based on local need. PHE continues to provide advice and support to local authorities on expanding naloxone provision.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2018-07-11", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "160729"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-07-11T11:32:10.51Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-07-04", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Naloxone"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the implications for his policies of the approval by the European Medicines Agency of nasal forms of naloxone to prevent deaths from opioid overdose; what progress his Department has made on implementing the guidance published by his Department entitled Widening the availability of naloxone; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3930", "label" : {"_value" : "Biography information for Caroline Lucas"} } , "tablingMemberConstituency" : {"_value" : "Brighton, Pavilion"} , "tablingMemberPrinted" : [{"_value" : "Caroline Lucas"} ], "uin" : "160730"} , {"_about" : "http://data.parliament.uk/resources/934777", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/934777/answer", "answerText" : {"_value" : "
The Department commissioned four independent separate systematic reviews of all relevant literature on the diagnosis, treatment, transmission and prevention of Lyme disease.<\/p>
<\/p>
The four systematic reviews were completed and published in December 2017 which assessed the existing evidence. The Department is aware of the findings which are available to the public, the research community and all research funders.<\/p>
<\/p>
We are investing over £1 billion a year in health research through the National Institute for Health Research (NIHR). The usual practice of the NIHR is not to ring-fence funds for expenditure on particular topics: research proposals in all areas compete for the funding available. The NIHR welcomes funding applications for research on Lyme disease including those that reflect the conclusions of the systematic reviews as part of its regular processes. All applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4008", "label" : {"_value" : "Biography information for Dame Caroline Dinenage"} } , "answeringMemberConstituency" : {"_value" : "Gosport"} , "answeringMemberPrinted" : {"_value" : "Caroline Dinenage"} , "dateOfAnswer" : {"_value" : "2018-07-12", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-07-12T11:03:04.06Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-07-04", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Lyme Disease"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to the report entitled Stakeholder experiences of the diagnosis of Lyme disease, A systematic review, published by Department of Health Reviews Facility in December 2017, what steps he has taken to improve the (a) diagnosis, (b) technology for and (c) testing of Lyme disease since the publication of that report.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3930", "label" : {"_value" : "Biography information for Caroline Lucas"} } , "tablingMemberConstituency" : {"_value" : "Brighton, Pavilion"} , "tablingMemberPrinted" : [{"_value" : "Caroline Lucas"} ], "uin" : "160731"} , {"_about" : "http://data.parliament.uk/resources/934201", "AnsweringBody" : [{"_value" : "Women and Equalities"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/934201/answer", "answerText" : {"_value" : "
GEO is working on what the interim funding will cover and how it will be delivered. The Minister for Women and Equalities is keen that the delivery model and the communications around it help reinforce that political parties have the prime responsibility for supporting their disabled candidates. Further details will be announced in due course.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4399", "label" : {"_value" : "Biography information for Victoria Atkins"} } , "answeringMemberConstituency" : {"_value" : "Louth and Horncastle"} , "answeringMemberPrinted" : {"_value" : "Victoria Atkins"} , "dateOfAnswer" : {"_value" : "2018-07-09", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-07-09T13:42:35.66Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "31"} , "answeringDeptShortName" : {"_value" : "Women and Equalities"} , "answeringDeptSortName" : {"_value" : "Women and Equalities"} , "date" : {"_value" : "2018-07-03", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Access to Elected Office for Disabled People Fund"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Minister for Women and Equalities, pursuant to the Answers of 2 July 2018 to Questions 158205 and 158206, on Access to Elected Office Fund, how she plans to promote the existence of the £250,000 of new funding announced on 17 May 2018; and such planned promotion is expected to start.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3930", "label" : {"_value" : "Biography information for Caroline Lucas"} } , "tablingMemberConstituency" : {"_value" : "Brighton, Pavilion"} , "tablingMemberPrinted" : [{"_value" : "Caroline Lucas"} ], "uin" : "160175"} , {"_about" : "http://data.parliament.uk/resources/933859", "AnsweringBody" : [{"_value" : "Ministry of Housing, Communities and Local Government"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/933859/answer", "answerText" : {"_value" : "